undamentalytics Newsletter
Sign in

Cartesian Therapeutics, Inc. income statement

In fiscal 2025, Cartesian Therapeutics, Inc. reported revenue of $2.8m, down 92.8% on the year before, operating income of −$143m (a -5127.1% margin) and net income of −$130m, or −$5.02 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3680171785111263931
Research and development10233045484355697271455868
General and administrative881319181619212440303132
Operating income−15−25−35−64−65−52−57−515−86−44−143−155
Interest expense11111223330——
Income before tax—————−55−69−1035−239−77−139—
Income tax—————0016−1−190−9—
Net income−13−25−36−65−65−55−69−2635−220−77−130−152
Diluted EPS−$11.76−$22.70−$29.18−$1.60−$1.46−$1.22−$0.68−$0.22$0.10−$49.76−$4.49−$5.02−$5.61
Diluted shares (average)1m1m1m1m1m2m3m4m5m5m17m26m27m
EBITDA−15−24−34−63−64−52−56−415−86−43−141−153

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABSI vs RNACOVID vs RNACDARE vs RNACLGVN vs RNAC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cartesian Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cartesian Therapeutics, Inc.